Captor Therapeutics SA
WSE:CTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Everest Consolidator Acquisition Corp
NYSE:MNTN
|
US |
|
Via SA
BOVESPA:VIIA3
|
BR |
|
J
|
JoulWatt Technology Co Ltd
SSE:688141
|
CN |
|
Letong Chemical Co LTD
SZSE:002319
|
CN |
|
H
|
Huaxi Holdings Company Ltd
HKEX:1689
|
HK |
|
S
|
Shenzhen iN Cube Automation Co Ltd
SZSE:301312
|
CN |
|
V
|
Vegetable Products Ltd
BSE:539132
|
IN |
|
Modine Manufacturing Co
NYSE:MOD
|
US |
|
Zhejiang Juhua Co Ltd
SSE:600160
|
CN |
|
T
|
TeamViewer AG
XETRA:TMV
|
DE |
|
Uday Jewellery Industries Ltd
BSE:539518
|
IN |
|
H
|
Hong Kong Resources Holdings Co Ltd
HKEX:2882
|
HK |
|
Zhejiang Huatie Emergency Equipment Science & Technology Co Ltd
SSE:603300
|
CN |
|
Toa Oil Co Ltd
TSE:5008
|
JP |
|
Truscreen Group Ltd
NZX:TRU
|
NZ |
|
H
|
H P Cotton Textile Mills Ltd
BSE:502873
|
IN |
|
Shreyans Industries Ltd
NSE:SHREYANIND
|
IN |
|
Chemcon Speciality Chemicals Ltd
NSE:CHEMCON
|
IN |
|
T
|
Tanco Holdings Bhd
KLSE:TANCO
|
MY |
|
ITI Ltd
NSE:ITI
|
IN |
|
N
|
Nichireki Co Ltd
TSE:5011
|
JP |
|
B
|
Bright Oceans Inter-Telecom Corp
SSE:600289
|
CN |
|
N
|
Net Lease Office Properties
NYSE:NLOP
|
US |
|
A
|
Anhui Guangxin Agrochemical Co Ltd
SSE:603599
|
CN |
Captor Therapeutics SA
EPS (Diluted)
Captor Therapeutics SA
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Captor Therapeutics SA
WSE:CTX
|
EPS (Diluted)
-zł8
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
M
|
Marvipol Development SA
WSE:MVP
|
EPS (Diluted)
zł1
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
M
|
MLP Group SA
WSE:MLG
|
EPS (Diluted)
zł8
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
7%
|
|
|
L
|
Lokum Deweloper SA
WSE:LKD
|
EPS (Diluted)
zł1
|
CAGR 3-Years
-16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
-2%
|
|
|
C
|
CFI Holding SA
WSE:CFI
|
EPS (Diluted)
zł0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-19%
|
|
|
D
|
Develia SA
WSE:DVL
|
EPS (Diluted)
zł0
|
CAGR 3-Years
23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
15%
|
|
Captor Therapeutics SA
Glance View
Captor Therapeutics SA engages in the development of protein degradation drugs for cancer and autoimmune diseases. The company is headquartered in Wroclaw, Woj. Dolnoslaskie and currently employs 98 full-time employees. The company went IPO on 2021-04-19. The firm works in the field of neoplastic and autoimmune diseases for which there is no treatment option, or the available methods show therapeutic limitations. The firm covers aspects of early-stage drug development to deliver therapeutics for life-threatening and life-impairing diseases. The broadly applicable Optigrade tm Targeted Protein Degradation (TPD) platform allows for the creation of new drugs.
See Also
What is Captor Therapeutics SA's EPS (Diluted)?
EPS (Diluted)
-8.3
PLN
Based on the financial report for Dec 31, 2024, Captor Therapeutics SA's EPS (Diluted) amounts to -8.3 PLN.
What is Captor Therapeutics SA's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-26%
Over the last year, the EPS (Diluted) growth was 46%. The average annual EPS (Diluted) growth rates for Captor Therapeutics SA have been -1% over the past three years , -26% over the past five years .
